Chemistry Testing on Plasma Versus Serum Samples in Dialysis Patients: Clinical and Quality Improvement Implications

被引:16
作者
Carey, Roger Neill [1 ]
Jani, Chinu [2 ]
Johnson, Curtis [3 ]
Pearce, Jim [4 ]
Hui-Ng, Patricia [5 ]
Lacson, Eduardo [6 ,7 ]
机构
[1] Spectra Labs, Dept Qual Syst, Rockleigh, NJ USA
[2] Spectra Labs, Dept Gen Adm, Rockleigh, NJ USA
[3] Spectra Labs, Dept Gen Adm, Milpitas, CA USA
[4] Spectra Labs, Dept Lab Adm, Milpitas, CA USA
[5] Spectra Labs, Dept Qual Syst, Milpitas, CA USA
[6] Tufts Med Ctr, Div Nephrol, Boston, MA USA
[7] Tufts Univ, Sch Med, Boston, MA 02111 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2016年 / 11卷 / 09期
关键词
HEPARINIZED PLASMA; ANALYZER; VALUES;
D O I
10.2215/CJN.09310915
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Plasma samples collected in tubes containing separator gels have replaced serum samples for most chemistry tests in many hospital and commercial laboratories. Use of plasma samples for blood tests in the dialysis population eliminates delays in sample processing while waiting for clotting to complete, laboratory technical issues associated with fibrin formation, repeat sample collection, and patient care issues caused by delay of results because of incompletely clotted specimens. Additionally, a larger volume of plasma is produced than serum for the same amount of blood collected. Plasma samples are also acceptable for most chemical tests involved in the care of patients with ESRD. This information becomes very important when United States regulatory requirements for ESRD inadvertently limit the type of sample that can be used for government reporting, quality assessment, and value based payment initiatives. In this narrative, we summarize the renal community experience and how the subsequent resolution of the acceptability of phosphorus levels measured from serum and plasma samples may have significant implications in the country's continued development of a value based Medicare ESRD Quality Incentive Program.
引用
收藏
页码:1675 / 1679
页数:5
相关论文
共 12 条
[1]  
[Anonymous], WHODILLAB991REV2
[2]  
Centers for Medicare & Medicaid Services(CMS), 2014, FED REGISTER, V79, P66119
[3]  
Centers for Medicare & Medicaid Services (CMS), 2013, FED REGISTER, V78, P72155
[4]  
CIUTI R, 1989, CLIN CHEM, V35, P1562
[5]  
DOUMAS BT, 1989, CLIN CHEM, V35, P151
[6]   Selected analyte values in serum versus heparinized plasma using the SYNCHRON LX PRO assay methods/instrument [J].
Er, Tze-Kiong ;
Tsai, Li-Yu ;
Jong, Yuh-Jyh ;
Chen, Bai-Hsiun .
LABMEDICINE, 2006, 37 (12) :731-732
[7]  
LUM G, 1974, AM J CLIN PATHOL, V61, P108
[8]   Haemostasis in chronic kidney disease [J].
Lutz, Jens ;
Menke, Julia ;
Sollinger, Daniel ;
Schinzel, Helmut ;
Thuermel, Klaus .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (01) :29-40
[9]   Comparison of serum and heparinized plasma samples for measurement of chemistry analytes [J].
Miles, RR ;
Roberts, RF ;
Putnam, AR ;
Roberts, WL .
CLINICAL CHEMISTRY, 2004, 50 (09) :1704-1706
[10]  
Ricós C, 1999, SCAND J CLIN LAB INV, V59, P491